Condition: Alzheimer Disease · Sponsor: Eli Lilly and Company
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of two parts, A and B. Each enrolled participant in Part A will receive a single dose of LY3954068 or placebo (no active drug) given into the spinal fluid. Each participant in Part B will receive 2 doses of either LY3954068 or placebo administered into the spinal fluid. Participants will have the opportunity to join an optional bridging period to a separate potential study where participants would receive LY3954068. The study will last up to approximately 45 weeks for Part A, and 100 weeks for Part B, including the screening period.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| K2 Medical Research, LLC | Maitland, Florida, United States | Recruiting |
| Charter Research, LLC | The Villages, Florida, United States | Recruiting |
| CenExel iResearch, LLC (CenExel iRA) | Decatur, Georgia, United States | Recruiting |
| Massachusetts General Hospital (MGH) | Charlestown, Massachusetts, United States | Not Yet Recruiting |
| CenExel AMRI | Toms River, New Jersey, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| The University of Tokyo Hospital | Bunkyō City, Japan | Recruiting |
| National Hospital for Neurology and Neurosurgery (UCLH) | London, United Kingdom | Recruiting |
| Royal Hallamshire Hospital | Sheffield, United Kingdom | Not Yet Recruiting |
| University Hospital Southampton | Southampton, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06297590